Background: Acute guttate psoriasis (AGP) is a distinctive clinical entity with good response to treatment with narrow-band ultraviolet B (NB-UVB). Objective: To investigate the results of NB-UVB phototherapy in adult patients with adult guttate psoriasis. Material and Methods: We carried out a prospective, open, and observational study. Patients over 18 years with more than 5% of body surface area affected were included. The PASI was assessed prior to and after treatment. The follow-up period was 18 months. After treatment, patients completed a simple questionnaire to assess their overall impression of the treatment. Results: The 67 adult patients with AGP included in this study had an initial PASI of 8.55 (SD 5.03). Patients were treated with a mean of 19.9 sessions (SD 13.5) and mean doses of 14 mJ/cm2 (SD 10.5). Of the 67 patients, 52 achieved PASI90 with 96.15% of PASI reduction, and of these, 46 (88%) maintained PASI90 during the 18 months of follow-up. Patients were very satisfied with the treatment. Discussion: AGP is a defined clinical entity with a variable course. Phototherapy with NB-UVB appears to be a very good option for treatment of AGP because of the good results obtained and patient satisfaction.

Keywords:
Psoriasis, Phototherapy, Narrow-band UVB, Treatment
1.
Griffiths CE, Christophers E, Barker JN, et al: A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007;156:258-262.
2.
Takahashi H, Nakamura K, Kaneko F, Nagakawa H, Lizuka H: Analysis of psoriasis patients registered with the Japanese society for psoriasis research from 2002-2008. J Dermatol 2011;38:1125-1129.
3.
Nahary L, Tamarkin A, Kayam N, et al: An investigation of antistreptococcal antibody responses in gutatte psoriasis. Arch Dermatol Res 2008;30:441-449.
4.
De Jager MEA, de Jong EMGJ, Meeuwis KAP, van de Kerkhof PCM, Seyger MMB: No evidence found that childhood onset of psoriasis influences disease severity, future body mass index or type of treatments used. J Eur Acad Dermatol 2010;24:1333-1339.
5.
Ko HC, Jwa SW, Song M, Kim MB, Kwon HS: Clinical course of guttate psoriasis: long-term follow-up study. J Dermatol 2010;37:894-899.
6.
Manolache L, Petrescu-Sceleanu D, Benea V: Life events involvement in psoriasis onset/recurrence. Int J Dermatol 2010;49:636-641.
7.
Almutawa F, Alnomair N, Wang Y, Hamazavi I, Lim HW: Systematic review of UV-based therapy for psoriasis. Am J Clin Dermatol 2013;14:87-109.
8.
Chen X, Yang M, Cheng Y, Liu GJ, Zhang M: Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev 2013;10: CD009481.
9.
Carrascosa JM, López-Estebaranz JL, Carretero G, et al: Documento de consenso de fototerapia en la psoriasis del Grupo Español de Psoriasis: ultravioleta B de banda estrecha (UVBBE), láser y fuentes monocromáticas de excímeros y terapia fotodinámica. Actas Dermosifiliogr 2011;102:175-186.
10.
Gokdemir G, Kivanç-Altunay I, Koslu A: Narrow-band phototherapy in patients with psoriasis: for which types of psoriasis is it more effective? J Dermatol 2005;32:436-441.
11.
Carvalho R, Marques-Pinto G, Cardoso J: Psoriasis phototherapy experience from a Lisbon unit: a still valid therapeutic approach in the 21st century. Cutan Ocul Toxicol 2013;32:78-82.
12.
Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE: Interventions for guttate psoriasis. Cochrane Database Syst Rev 2000;2: CD001213.
13.
Pathirana D, Ormerod AD, Saiag P, et al: European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23:1-70.
14.
Cameron H, Dawe RS, Yule S, et al: A randomized, observer-blinded trial of twice vs three times weekly narrow band ultraviolet B phototherapy for chronic plaque psoriasis. Br J Dermatol 2002;147:973-978.
15.
Behrens S, Grundmann-Kollmann M, Schiener R, et al: Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 2000;42:493-495.
16.
Brands S, Brankman M, Bos J, et al: No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis. J Am Acad Dermatol 1999;41:991-995.
17.
Kirke SM, Lowder S, Lloyd JJ, et al: A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. J Invest Dermatol 2007;127:1641-1646.
18.
Boztepe G, Karaduman A, Sahin S, Hayran M, Kolemen F: The effect of maintenance narrow-band ultraviolet B therapy on the duration of remission for psoriasis: a randomized trial. Int J Dermatol 2006;45:245-250.
19.
Puig L, Carrascosa JM, Carretero G, et al: Directrices basadas en la evidencia para el tratamiento de la psoriasis con fármacos biológicos 2013. Actas Dermosifiliogr 2013;104:694-709.
20.
Martin BA, Chalmers RJ, Telfer NR: How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? Arch Dermatol 1996;132:717-718.
21.
Ferrandiz C, Pujol RM, Garcia-Patos V, et al: Psoriasis of early and late onset: a clinical and epidemiologic study in Spain. J Am Acad Dermatol 2002;46:867-873.
22.
Williams RC, McKenzie AW, Roger JH, Joysey VC: HL-A antigens in patients with guttate psoriasis. Br J Dermatol 1976:95:163-167.
23.
Mallbris L, Larsson P, Bergqvist S, et al: Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases. J Invest Dermatol 2005;124:499-504.
24.
Naldi L, Peli L, Parazzini F, Carrel CF: Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case control study. J Am Acad Dermatol 2001;44:433-438.
25.
Nahary L, Tamarkin A, Kayam N, et al: An investigation of antistreptococcal antibody responses in gutatte psoriasis. Arch Dermatol Res 2008;30:441-449.
26.
Dogan B, Karabudak O, Harmanyeri Y: Antistreptococcal treatment of gutatte psoriasis: a controlled study. Int J Dermatol 2008;47:950-952.
27.
Finch T, Shim TN, Roberts L, Johnson O: Treatment satisfaction among patients with moderate to severe psoriasis. J Clin Aesthet Dermatol 2015;8:26-30.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.